All In Biotech

Investigational drug · Phase 3

Maridebart cafraglutide

Also called: AMG 133

Not approved by FDA. In 14 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obesity, Overweight, Obstructive Sleep Apnea.

Phase 3

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

14

14 still active

All registered trials

30

Any phase or sponsor naming "Maridebart cafraglutide"

First trial start

2024

Nov 7, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Maridebart cafraglutide", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Obesity
  • Overweight
  • Obstructive Sleep Apnea
  • Diabetes Mellitus, Type 2
  • Obesity or Overweight
  • Heart Failure With Preserved Ejection Fraction
  • Heart Failure With Mildly Reduced Ejection Fraction
  • Overweight or Obesity and Elevated Liver Fat
  • Atherosclerotic Cardiovascular Disease
  • Obesity Disease

Approved drugs for the same conditions: Obesity and weight management · Heart failure · Cardiovascular and metabolic · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "Maridebart cafraglutide" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 21 on PubMed

Also in development for Obesity

  • CagrilintidePhase 320 trials

    Novo Nordisk · Obesity, Overweight, Type 2 Diabetes

  • BerobenatidePF-08653944, MET097Phase 319 trials

    Pfizer · Obesity, Overweight and/or Obesity, Overweight

  • RetatrutideLY3437943Phase 316 trials

    Eli Lilly · Obesity, Overweight, Type 2 Diabetes

  • EloralintideLY3841136Phase 313 trials

    Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2

  • HRS9531Phase 313 trials

    Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)

  • NNC0487-0111Phase 312 trials

    Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea

  • HRS-7535Phase 310 trials

    Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity

  • UBT251Phase 310 trials

    The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Amgen.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.